Last reviewed · How we verify
Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Approved treatments
- Fabrazyme (agalsidase beta) · Genzyme, a Sanofi Company
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease treatment landscape brief
- Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease treatment updates RSS
Frequently asked questions about Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
What drugs treat Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease?
Tracked treatments include Fabrazyme (agalsidase beta).
What is the treatment for Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease?
Standard treatment for Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease includes Fabrazyme (agalsidase beta). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease patent cliff · Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease CI report
- Treatment: Fabrazyme (agalsidase beta) · Genzyme, a Sanofi Company
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing